Medication Switch Guide
Switching from Semaglutide to CagriSema: Dose Conversion & Timeline
Whether you're switching because of side effects, insurance changes, or a desire to optimize your response, transitioning from Semaglutide to CagriSema requires a structured approach. This guide summarizes the clinical evidence and practical protocol.
⚠️ Medical Disclaimer
This page is for educational purposes only and does not constitute medical advice. GLP-1 medications are prescription drugs. Discuss all treatment decisions with a licensed healthcare provider who knows your complete medical history. Individual results vary significantly from clinical trial averages.
🔔 Always switch under prescriber supervision
Switching GLP-1 medications should be guided by a licensed clinician. Do not self-transition. Dose equivalence tables are approximations — individual response varies.
Why Switch from Semaglutide to CagriSema?
Common clinical reasons for switching include:
- Efficacy: Seeking greater weight loss efficacy (22.7% vs 14.9%)
- Tolerability: Side effects on Semaglutide that may differ with CagriSema's distinct mechanism or formulation
- Insurance/cost: Formulary changes or coverage shifts favoring CagriSema
- Mechanism upgrade: CagriSema is a GLP-1 receptor agonist + Amylin analog (cagrilintide) vs Semaglutide's GLP-1 receptor agonist
⚠ Note: CagriSema is currently Phase 3 and not commercially available. This guide is for educational purposes only and does not constitute prescribing guidance.
Dose Equivalence Table
There are no formally established dose equivalence conversions between most GLP-1 medications — each drug has its own dose-response curve and receptor binding profile. The general approach is to restart at the lowest titration dose of the new agent regardless of dose achieved on the prior agent.
| When on Semaglutide | Start CagriSema at | Rationale |
|---|---|---|
| Any dose | 0.25 mg (weekly) | Standard re-titration recommended for all switches |
| 2.4 mg (max dose) | 0.25 mg → escalate per schedule | Even patients at maximum doses re-titrate from the starting dose |
Washout Period
No washout period required for weekly-to-weekly GLP-1 transition. The last dose of the previous drug can be substituted directly with the first dose of the new drug at the starting (titration) dose.
Semaglutide has a half-life of approximately 168 hours. CagriSema has a half-life of approximately 168 hours. These pharmacokinetic differences influence the transition protocol but rarely require a true drug-free washout period for GLP-1 class switches.
What to Expect: First 4 Weeks on CagriSema
Patients switching to a new GLP-1 agent often experience a re-emergence of GI side effects (nausea, diarrhea, constipation) during the re-titration period, similar to what occurred when starting the first medication. This is normal and expected — the body is adapting to a new receptor agonist profile.
- Week 1–2: May experience mild nausea, especially if CagriSema has a higher receptor affinity at baseline than Semaglutide
- Week 2–4: GI symptoms typically stabilize; weight loss progress may briefly stall during re-titration
- Week 4+: Begin first dose escalation if dose is well tolerated
- Week 12–24: Expect to see meaningful efficacy data from the new agent
Monitoring After Switching
- Schedule a follow-up at 4–8 weeks post-switch to assess tolerability and early efficacy
- Monitor weight, blood glucose (if diabetic), and GI symptom pattern
- Ensure adequate hydration throughout re-titration period
- Report any unexpected or severe adverse events promptly
Drug Comparison: Semaglutide vs CagriSema
| Feature | Semaglutide | CagriSema |
|---|---|---|
| Mechanism | GLP-1 receptor agonist | GLP-1 receptor agonist + Amylin analog (cagrilintide) |
| Weight Loss (%) | 14.9% | 22.7% |
| Frequency | Weekly | Weekly |
| FDA Status | Approved 2021 | Phase 3 |
For a full comparison, see our Semaglutide vs CagriSema comparison page.
📅 Dose Schedule Calculator
Plan your CagriSema titration schedule after switching from Semaglutide.
Plan My CagriSema Schedule →